Huaxia Eye Hospital GroupLtd Future Growth
Future criteria checks 3/6
Huaxia Eye Hospital GroupLtd is forecast to grow earnings and revenue by 20.5% and 18% per annum respectively. EPS is expected to grow by 20.4% per annum. Return on equity is forecast to be 14.4% in 3 years.
Key information
20.5%
Earnings growth rate
20.4%
EPS growth rate
Healthcare earnings growth | 22.7% |
Revenue growth rate | 18.0% |
Future return on equity | 14.4% |
Analyst coverage | Low |
Last updated | 20 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 6,571 | 1,173 | 1,504 | 1,451 | 3 |
12/31/2025 | 5,993 | 1,045 | 840 | 1,300 | 5 |
12/31/2024 | 4,800 | 818 | 754 | 1,064 | 3 |
3/31/2024 | 4,061 | 672 | 405 | 867 | N/A |
12/31/2023 | 4,013 | 666 | 513 | 961 | N/A |
9/30/2023 | 3,813 | 674 | 517 | 880 | N/A |
6/30/2023 | 3,648 | 632 | 510 | 798 | N/A |
3/31/2023 | 3,355 | 552 | 656 | 872 | N/A |
1/1/2023 | 3,233 | 514 | 535 | 770 | N/A |
9/30/2022 | 3,297 | 516 | 688 | 871 | N/A |
1/1/2022 | 3,064 | 455 | 624 | 798 | N/A |
9/30/2021 | 2,998 | 445 | 552 | 731 | N/A |
12/31/2020 | 2,515 | 334 | 427 | 591 | N/A |
12/31/2019 | 2,456 | 218 | 188 | 444 | N/A |
12/31/2018 | 2,146 | 164 | -47 | 291 | N/A |
12/31/2017 | 1,543 | 78 | N/A | 298 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301267's forecast earnings growth (20.5% per year) is above the savings rate (2.9%).
Earnings vs Market: 301267's earnings (20.5% per year) are forecast to grow slower than the CN market (23.3% per year).
High Growth Earnings: 301267's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 301267's revenue (18% per year) is forecast to grow faster than the CN market (14% per year).
High Growth Revenue: 301267's revenue (18% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 301267's Return on Equity is forecast to be low in 3 years time (14.4%).